WP3 Strategic analysis of the future perspectives for cooperation and coordination Summary of the expert workshop on the European Research Agenda (WP 3)

Slides:



Advertisements
Similar presentations
06/02/ Mechanisms to enhance synergy between ERA-NETs within and between research councils Eili Ervelä-Myréen
Advertisements

Slide 1 Research in support to Human Biomonitoring E&H, Consultative Forum Meeting 19 October 2005 Luxembourg P. Valette DG Research, Directorate Environment.
Integrating the gender aspects in research and promoting the participation of women in Life Sciences, Genomics and Biotechnology for Health.
Hungarian GEnomic Research on pathogenic Microbes Hu-GERM.
Oficina AproTECH de AETIC: Información y asesoramiento en la preparación de propuestas de I+D+I The structure of the FP7: Funding schemes,
Indridi Benediktsson June 2007 International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination.
Biotechnology Chapter 11.
Course Advice for B. Science and B. Biomedicine students GENETICS MAJOR.
Transcriptomics Breakout. Topics Discussed Transcriptomics Applications and Challenges For Each Systems Biology Project –Host and Pathogen Bacteria Viruses.
Characterizing Uncultured Bacteria Michael Wagner Division of Microbial Ecology University of Vienna.
Case Testimony of the Participation of One Particular Laboratory to the European Research Programmes in Life Sciences (4th and 5th Frameworks) Prof. Dr.
Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.
EoI assesment and presentation NCP 24 October 2002 Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related.
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
Dr Costas Papaconstantinou
Sequencing capacitiesacademic company based microarray facilitiesacademic company based bioinformaticsacademic proteomic facilitiesacedemic Genome Research.
Unit 1: The Language of Science  communicate and apply scientific information extracted from various sources (3.B)  evaluate models according to their.
Microbiology and Human Disease Overview of Microbiology.
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
The BIO Directorate Microbial Biology Emphasis BIO Advisory Committee April, 2005.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
1 Progress report: DISCONTOOLS Project Morgane Delavergne DISCONTOOLS Project Manager, September 22nd, 2009 Mirror Group Meeting Châtelain Hotel, Brussels.
A new antivirulence approach against pathogenic bacteria A new antivirulence approach against pathogenic bacteria May 2005 Sonia Escaich - President &
Physiological Integration in Organismal Biology Hannah V. Carey, Ph.D. Department of Comparative Biosciences University of Wisconsin School of Veterinary.
ERA-NET PathoGenoMics Meeting Bonn 7-8 April, 2005 Research topics of interest in the Area of Genomics of Bacterial and Fungal Pathogens of Humans Prof.
Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.
Host-Microbe Interactions Chapter 14. Disease Etiology Pathogen –Primary vs. opportunistic Virulence.
Overview of operational research in MSF Myriam Henkens, MD, MPH International Medical Coordinator MSF London 1st of June, 2006.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
MICROBES AND MAN Research Programme October 13, 2004 Berlin Soile Juuti Programme manager Finland.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
P ATHO G ENO M ICS PORTUGAL Partner 9 P ATHO G ENO M ICS PORTUGAL Partner 9.
1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.
Prof. dr. J.Fink-Gremmels DVM, PhD, Dip ECVPT President EAVPT MP-EU EPP: Antimicrobial resistance: urgent need to act in human.
Pathogenomics in France Philippe Glaser. Administrative situation Creation of the ANR (Agence National pour la Recherche) - National Research Agency –Delay.
Evolutionary medicine diseases tracking hosts, and jumping to new hosts virulence evolves resistance evolves antibiotics and evolutionary responses openclipart.org.
Building the Europe of Knowledge Proposals for the 7 th Research Framework Programme
Humans and the Microbial World Chapter 1. What is a Microorganism? 1.Definition 2.Prokaryotic or Eukaryotic? 3.Unicellular or Multicellular?
SECRETARÍA DE ESTADO DE UNIVERSIDADES E INVESTIGACIÓN Dirección General de Investigación 1 MINISTERIO DE EDUCACIÓN Y CIENCIA The Spanish National Programmes,
Seventh Framework Programme Theme 1 - Health Ph D.Olguta Iordache Health - NCP.
Peer Learning Event on national Lifelong Guidance Policy Forums 4th-5th of June 2008, Thessaloniki With the support of the Lifelong Learning Programme.
Pathogenomics How this project began: Ann Rose - take advantage of DNA sequence information - genomics Julian Davies - use the information to understand.
E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.
ESI workshop Stochastic Effects in Microbial Infection The National e-Science Centre Edinburgh September 28-29, 2010.
GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership.
Alun JONES EU Network Manager European Agency for Safety and Health at Work 6 th Framework Programme on Research.
Future outlook and next steps for ESPON The ESPON 2013 Programme OPEN DAYS Bruxelles, 10 October 2007.
Post-genomic Virology The impact of bioinformatics, microarrays and proteomics on investigating host and pathogen interactions Steven Masson.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Implementation plan for Strategic Research and Innovation Agenda for Traditional Food Prof. Đuro Kutlača, PhD Institute “Mihajlo Pupin”, University of.
1 Modelling and Simulation EMBL – Beyond Molecular Biology Physics Computational Biology Chemistry Medicine.
Genome sequencing of disease causing microorganism Romana Siddique.
A European Academic Network for Vaccine Research An Idea from the Danish Mirror Group under ETPGAH Working group: Jens Kjær – Boehringer Ingelheim DK Poul.
Research on Antimicrobial Resistance
Third Meeting of National Contact Points
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Principles of Medical Microbiology
INTRODUCTION TO ENVIRONMENTAL MICROBIOLOGY
A new antivirulence approach against pathogenic bacteria
Gene Transfer, Genetic Engineering, and Genomics
G. Cornaglia, A. Lönnroth, M. Struelens 
BSc (Hons) Agri-Biosciences
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Role of the Microbiota in Immunity and Inflammation
SRIA Roadmap Jonathan Pearce
Introduction/Terminology
Info Day on New Calls and Partner Café
M-H Pinard-van der Laan
Presentation transcript:

WP3 Strategic analysis of the future perspectives for cooperation and coordination Summary of the expert workshop on the European Research Agenda (WP 3)

Objectives of WP3 WP 3 and 4 are designed to lay the strategic foundations of joint and transnational activities. With regard to the scientific and technological issues, WP 3 Strategic analysis of the future perspectives for cooperation and coordination analyses the complementarity between the partner countries´ programmes (or programme areas), topics of common interest, new ideas for potential future cooperations, new demands/opportunities in the field, as well as overlaps/redundancies and gaps. To implement this step of networking, strategically oriented workshops of programme makers with leading scientists will be organised. Based on the outcome of these workshops, selected “rapporteurs” will formulate a European research agenda for pathogenomics-related research.

Annex I Pathogenomics: A Proposed European Research AGENDA The development of genomic technologies and bioinformatics to provide novel opportunities for studying life-threatening human pathogens with great potential of enhancing human health A: The microbes 1.Microbial ecology and populations 2.Metabolism and signalling 3.Evolution of microbial virulence and antibiotic resistance 4.Biofilm formation 5.Genome plasticity and gene pools 6.Antigenic diversity and variation 7.Unculturable microorganisms 8.Relation between pathogenic and non pathogenic related species 9.Environmental reservoir

B: Host-microbe interactions 1.In vivo pathogenesis of infections caused by bacterial and fungal microorganisms with the capacity of affecting human health 2.Mechanisms underlying breakage of epithelial and endothelial barriers (blood-brain; gut epithelium; pulmonary epithelium; placenta...) a.Receptors and cell surface structures of the host cell b.Bacterial cell surface structures c.Cell-cell communication 2.2 Metabolic interactions and adaptations of host cells and bacteria 3.Evasion of the host immune defences 4.Commensalism and nosocomial infections 5.Secondary pathologies (eg cancer and autoimmune diseases) induced in the host 6.Probiotics, role of the resident flora

C: Development and improvement of tools 1.Development of new bioassays for the identification of novel targets for therapy and vaccination 2.Novel diagnostic approaches 3.Metagenomics of microbial communities 4.New in vitro screening techniques 5.Bioluminescence (and other) imaging techniques to follow infections in vivo 6.Microarrays and proteomics of infected tissues 7.Animal models by transgene techniques 8.Establishment of strain and tissue collections 9.Databases and data analysis techniques

Priorities for the first call (Bonn April 05) What is pathogenomics? The application of global methods and genome based approaches to study + Bacterial and fungal human pathogens + Related non-pathogenic species + Host response to the pathogen Pathogenomics is not The study of viruses or parasites Random screening for antimicrobial compounds Research topics should include: Microbial community ecology, reservoirs, asymptomatic infections Commensalism / virulence transition Manipulation and exploitation of the host by the pathogen Evolution of microbial virulence, fitness and antibiotic resistance Regulatory networks and metabolism of the pathogen in the host

Objectives of the meeting Prospective discussion between leading scientists in the field of Pathogenomics Define what is Pathogenomics To identify major trends in the field of pathogenomics To publish the conclusion as a research agenda To refine priorities for the first call

Divining the Future of Microbiology A committe convened to puzzle out where trends in microbiology may lead provides some intriguing projections By Christon J. Hurst ASM News June 2005 Understanding microbial interrelationships and interactions: microbial ecology communities & metagenome Health of humans and of the world: infectious dose response, agricultural use of antibiotics, new vaccines, interaction between humans and microbes, infections and cancer, evolution and emergence of pathogens, survival of pathogens in the environment. Microbiology as a whole: … microbial life beyond our planet. Biology as a whole: co-evolution and its immunological significance (horizontal gene transfer)

Organization of the meeting Section 1: Host-microbe interaction (7 speakers) Section 2: technological developments (4 speakers) Section 3: The microbes (8 speakers) Section 4: Industries and Pathogenomics (3 speakers) Section 5: Transversal activity (3 speakers) Group discussion on each theme

The subject of the talks Description of the research activity in the country with examples related to Pathogenomics High quality of the talks with interesting highlights on specific projects Difficulty to define priorities Better definition of new fields through new technological approaches

Priority in pathogenomics Need to improve interactions with other disciplines –Mathematics : system biology –Physics : in vivo imaging, fluorescent methods, single cell and single molecule studies –Chemistry : identification of (new) functions of “unknown” proteins Need for technological innovation (example in proteomics) Importance of animal models : –Alternative model to the mouse model of infection –Use of RNAi to study gene function –Transgenic mice (humanized) and xenografts

Outcomes of the meeting Interesting but not exhaustive view on the research activity in the field of Pathogenomics in the ten participating countries Several new themes, which deserved to be considered in the future calls. Some ambitious goals which will require cooperation at the European level Importance of the cooperation with the industry Difficulty to define the specificity of Pathogenomics, in a context where study of infectious diseases integrates focused and global approaches Difficulty to go behind these general statements in the frame of a meeting of 25 scientists

The next step To constitute a smaller discussion group of 6 to 8 participants to prepare the final agenda To better define the specificity of Pathogenomics To combine discussion with WP4 “analyses the complementarity between the partner countries´ programmes (or programme areas), topics of common interest, new ideas for potential future cooperations, new demands/opportunities in the field, as well as overlaps/redundancies and gaps“.  Need to extend the duration of wp3 to 24 months